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Abstract. 
Bevacizumab is known to be a humanized monoclonal antibody that inhibits vascular en-
dothelial growth factor. It is used to treat varied kinds of cancers, such as breast cancer, colo-
rectal cancer, non-small cell lung cancer, high grade glioma and etc. While it do appear to de-
lay cancer progression, it is not a curative approach. Because of its high molecular weight, 
bevacizumab would be believed to be not cross the blood- brain barrier. However, this theory is 
to be challenged by series of studies proving the efficacy of bevacizumab in brain tumor. On 
account of lack of vital information about safety events and increasing risk of intra-cranial 
hemorrhage, Food and Drug Administration (FDA) lifted the ban on use of bevacizumab in 
colorectal cancer with brain metastasis since several years ago. Therefore, the reports of use of 
bevacizumab in colorectal cancer with brain metastasis are limited. Here, we presented a case 
of colorectal cancer with brain metastasis, and the brain lesion got shrinkage after starting 
bevacizumab in combination with chemotherapy. 
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中文摘要 
  Bevacizumab 是一種人工合成單株性抗體主要可抑制血管內皮細胞生長因子，目前被
廣泛運用在許多癌症，例如乳癌、結腸直腸癌，非小細胞肺癌以及高度膠質瘤等等，主
要目的在於延緩疾病的惡化，而非讓疾病獲得治癒。因為高分子量，bevacizumab 在以往
都被視無法穿透血腦屏障，然而根據一些關於其對腦瘤的療效的研究，bevacizumab 目前
被相信仍會有部分穿透血腦屏障的能力，但儘管如此由於其缺乏全盤安全性資料以及會
增加顱內出血的機率，在多年前美國食品藥物管理局已經將 bevacizumab 對於大腸直腸癌
合併腦轉移的適應症撤銷，因此目前關於其對於大腸致腸癌合併腦轉移治療相關的研究
極少。在這篇文章中，我們呈現一位結腸直腸癌合併腦轉移病患在接受 bevacizumab 合併
化學治療後腦病灶明顯縮小的案例。 
關鍵字: 生物化學治療、bevacizumab、癌思停、結腸直腸癌、腦轉移 
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 INTRODUCTION 
Colorectal cancer is a major cause of death 
throughout the world, and the frequency of this kind 
of cancer has increased two to four fold in Asian 
countries during the past few decases [1,2]. In 2008, a 
new kind of colorectal cancer occurred in 1.2 million 
people, and it accounted for 9.7% of all cancers [3,4]. 
In Taiwan, its proportion was up to 14.3% [5]. Alt-
hough the incidence of the colorectal cancer is com-
monly higher than those of other malignancies, brain 
metastasis occurs rather infrequently in colorectal 
cancer. With the advances in treatment of colorectal 
cancer, the overall survival has been prolongd over the 
past decades. However, for unresectable disease, the 
five-year overall survival rate has remained low, been 
estimated to be less than 10% [6]. The cumulative in-
cidence of brain metastasis originating from colorectal 
cancer 5 years after initial treatment is estimated to be 
1-2% [7-9]. We believe that the rate of brain metasta-
sis in colorectal cancer will rise continuously as the 
survival of patients is prolonged. 
The mechanism of brain metastasis remains un-
clear, but the affinity between cancerous cells and 
neuronal tissues may be involved in the process [10]. 
In one study, its authors restrospectively identified 17 
patients with brain metastasis and concluded that 
higher neural cell adhesion molecule (NCAM) ex-
pression in primary colorectal cancer was in associa-
tion with a higher incidence rate of brain metastasis 
[11]. 
Overexpression of the vascular endothelial growth 
factor that increases vascular permeability and inter-
stitial fluid pressure is critical for vascular prolifera-
tion and tumor survival. Therefore, it is reasonable to 
support that bevacizumab, a humanized monoclonal 
antibody to vascular endothelial growth factor, can 
suppress new blood vessel growth and existence. It was 
provided in first-line and second-line bevacizumab- 
naïve settings in combination with 5-fluorouracil 
(5-FU)–based therapy to metastatic colorectal cancer 
[12,13]. Because of its efficacy and manageable tox-
icity, it was approved by the FDA for patients with 
metastatic colorectal cancer on February 26, 2004. 
However, the role of bevacizumab in the treatment of 
brain metastases is still unclear. In the past, bevaci-
zumab was believed to be useless in brain metastasis 
because of its limited ability to cross the blood-brain 
barrier. But in animal models, bevacizumab was 
shown to be effective in brain tumor [14]. In some 
case reports [15-17] and also in a phase II study [18], 
the clinical benefit of bevacizumab in patients with 
colorectal, breast and non-small cell lung cancers with 
brain metastases was proven. Although the mecha-
nism is not completely clarified, we believe, at least in 
part, it is due to blood-brain barrier reconstitution and 
vascular normalization. This is probably why penetra-
tion of the blood-brain barrier is not required for intra- 
tumoral penetration. In this article, we present a clini-
cal course of a complicated case with colorectal can-
cer with brain metastasis, and the patient’s condition 
improved after use of bevacizumab. 
 
CASE REPORT 
In May 2010, a 57-year-old female presented with 
bloody stools for two weeks. Colonoscopy was then 
performed at an outside institution and showed an ul-
cerative tumor six to fifteen centimeters from the anal 
verge. To seek a second medical opinion, the patient 
was transferred to our hospital. After the second co-
lonoscopy, the patient was diagnosed to have adeno-
carcinoma of the rectum on the basis of the biopsy. 
Baseline computed tomography (CT) of the chest and 
abdomen showed multiple small nodules in lung fields 
bilaterally and in both hepatic lobes. Increased soft 
tissue density in the right lower quadrant of the abdo- 
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Figure 1. Contrast enhanced CT of brain showing. (A) A heterogenous enhancing soft tissue nodule 15 millime-
ters in dimension with prominent perifocal edema, in left parasagital high parietal region; (B) An en-
hancing nodule 7 mm in dimension with mild perifocal edema, at right occipital pole 
 
 
men was also noted on the CT. Therefore, the final 
diagnosis was adenocarcinoma of the rectum with per-
itoneal seeding, liver and lung metastases, and ac-
cording to the American Joint Committee on Cancer 
(AJCC), clinical stage T3N2M1. The baseline carci-
noembryonic antigen (CEA) level was 980 ng/ml, 
Subsequently, the patient underwent a radical proctec-
tomy with low anterior resection plus lymph node 
dissection and bilateral salpingo oophorectomy in 
June, 2010. And the surgical stage of the tumor was 
compatible with the clinical one which was mentioned 
above. Adjuvant chemotherapy with FOLFOX (5-FU, 
leucovorin and oxaliplatin) was administered in 6 
cycles. We changed the chemotherapy regimen to 
FOLFIRI (5-FU, leucovorin and irinotecan) in Octo-
ber, 2010 because of increased size of pulmonary 
nodular lesions. In October 2010, the patient was 
found to have nausea, intermittent headache and diz-
ziness. Subsequent CT of the brain revealed two het-
erogenous enhancing nodules with perifocal edema. 
One was fifteen millimeters in dimension in the left 
parasagital high parietal region and the other, seven 
millimeters in dimension in the right occipital lobe 
(Figure 1). We performed the magnetic resonance im-
aging (MRI) of the brain (Figure 2) and its result was 
compatible with the findings of CT. Under the diagno-
sis of brain metastasis, the patient received whole- 
brain radiotherapy with 3600 cGy in 12 fractions dur-
ing the hospitalization. Xeloda was concurrently used 
with radiotherapy following three cycles of XELIRI 
(Xeloda, leucovorin and irinotecan). After therapy, the 
brain lesions were in stable condition, and the pa-
tient’s neurological symptoms improved gradually. 
However, the pulmonary lesions remained progressing, 
and we added cetuximab to XELIRI subsequently. 
After five cycles of cetuximab plus XELIRI and sub-
sequent three cycles of XELIRI, a follow-up chest CT 
taken in May, 2011 and it revealed that the pulmonary 
lesions seemed to be still progressive. The patient’s 
nausea and dizziness became worse, and she devel-
oped unstable gait in June, 2011, while brain lesions 
remained stationary on the CT (Figure 2A, 2B).  
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Figure 2. Comparison of contrast-enhanced CT of brain before bevacizumab (A, B) and the one after bevaci-
zumab (C, D) showing shrinkage of brain lesions 
 
 
Therefore, the patient started on Bevacizumab plus 
XELIRI in July, 2011. Dramatically, the following 
brain CT in August showed shrinkage of the brain le-
sions (Figure 2C, 2D). In spite of the improvement of 
the brain lesions and neurological symptoms, the sys-
temic lesions (lung, liver, and peritoneal carcinomato-
sis) progressed after our therapy. In October, 2011, the 
patient presented with vomiting with massive coffee 
ground material and severe dyspnea. After receiving 
medical treatment, the patient was eventually referred 
to a hospice. 
 
DISCUSSION 
Since last decades, bevacizumab combined with 
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 intravenous 5-FU–based drugs have become the first 
line therapy for patients with metastatic colorectal 
cancer. However, its role in the metastatic brain le-
sions originating from the colorectal cancer is still 
unclear because of the limited number of cases in 
clinical trials. A case report [15] similar to ours pub-
lished in 2008 first presented the therapeutic effect of 
bevacizumab in a patient with colorectal cancer with 
brain metastasis. Here, we have presented a case of 
adenocarcinoma of the rectum with multiple metasta-
ses. Even at the begining, the patient already had ex-
tensive metastatic disease to the liver, lung, and peri-
toneum. Metastatic brain lesions, however developed 
during her therapeutic course. According to the pre-
vious analytic data, one year median survival was less 
than 1% for the patients with brain metastasis [19]. 
For our patient, the duration of her survival period 
was 14 months after the confirmed diagnosis. We be-
lieve that the patient’s longer survival period was at-
tributed to the progressive and aggressive treatment. 
Tracing our patient’s treatment and clinical 
presentation, we find that the brain lesions remained 
stable under series of treatments started in October, 
2010. During this period, the treatments included XE-
LIRI and cetuximab. After addition of bevacizumab, 
the brain lesions began to show regressive change on 
the image study, and the patient’s neurological symp-
toms improved subsequently. 
In a retrospective study [20], the authors reviewed 
14 patients with recurrent glioma who have been 
treated with bevacizumab and chemotherapy. Seven 
patients (50%) showed partial response on MRI. The 
effect of bevacizumab was presumed not only to re-
duce peri-focal edema but also to directly inhibit gli-
oma cells. Notablely, the response occurred in as few 
as 18 days after the initiation of therapy. For our case, 
the response was noted 45 days after the beginning of 
bevacizumab by the evidence of brain CT. In fact, the 
response was noted earlier clinically.  
In a case report which was published in 2010 [21], 
the authors presented a 54-year-old woman with met-
astatic infiltrating ductal breast carcinoma which de-
veloped brain metastasis. After microsurgical resec-
tion followed by stereotactic radiosurgery, bevaci-
zumab was administered for six months. After the six 
months’ therapy of bevacizumab, a newly enhanced 
nodular lesion was noted on the brain MRI. By histo-
pathologic examination, the new lesion was still the 
metastatic breast cancer. After discontinuation of 
bevacizumab, the enhanced nodular lesions developed 
again. Thus, the authors concluded bevacizumab 
would alter neuroimaging characteristics. Compared 
with this case, our patient did not have resection and 
continued to be placed on bevacizumab for three 
months. Because of improvement of neurologic defi-
cits, we believe that the shrinkage of brain lesions on 
the brain CT reflected tumor in regression instead of 
showing a masking effect of the bevacizumab.  
 
CONCLUSIONS 
The therapeutic advantage seemed to be obvious 
and impressive in our case hereby presented. However, 
large scale clinical trials are necessary for a complete 
understanding of the exact therapeutic mechanisms of 
bevacizumab. 
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